Atakan Arslan
Research Subjects
Research Interests
Atakan Arslan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Erdem Yaka
Division of Critical Care Medicine, Department of Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye
1 shared publication - Kursad Kutluk
Independent Researcher, 35340 Izmir, Türkiye
1 shared publication - Nurcan Akbulut
Izmir Katip Celebi University Atatürk Education and Research Hospital
1 shared publication - Süleyman Men
Dokuz Eylul University Faculty of Medicine, Department of Radiology, İzmir, Turkey
1 shared publication - Vesile Öztürk
Department of Neurology, Faculty of Medicine, Dokuz Eylül University, İzmir, Türkiye
1 shared publication - Zeynep Tuncer
Department of Neurology and Pain Clinic, Sakarya Adatıp Hospital, Sakarya, Turkey
1 shared publication
Latest Publications
- 28 October 2021
- Published by Taylor & Francis in Neurological Research
- Vol. 44 (4) , 353-361
Factors associated with early improvement after intravenous thrombolytic treatment in acute ischemic stroke
: The aim of this study was to determine the factors associated with early neurological improvement (ENI) in patients who experienced acute ischemic stroke and were treated with intravenous recombinant tissue plasminogen activator (IV rt-PA), and determine the relationship with the outcome at the first control. : This study included 377 patients who were treated with IV rt-PA in Izmir Dokuz Eylül University Hospital between January 2010 and October 2018. ENI was defined as a 4 or more improvement in the National Institutes of Health Stroke Scale (NIHSS) score in the first hour, the twenty-fourth hour and the seventh day when compared to the pretreatment phase. The modified Rankin Scale (mRS) 0–1 score was defined as ‘very good outcome’. : The basal NIHSS (p=0.003, p=0.003, p=0.022) was high in the first hour, twenty-fourth hour, and seventh day ENI groups. Blood urea nitrogen (BUN) level was low in the first- and twenty-fourth-hour ENI groups (p=0.007, p=0.020). Furthermore, admission glucose was low at the twenty-fourth hour and on the seventh day ENI groups (p=0.005, p=0.048). A high infarct volume was observed on magnetic resonance imaging (MRI) at the twenty-fourth hour and on the seventh day non-ENI groups (p= <0.001, p= <0.001). : Management of factors associated with ENI and determination of treatment strategies accordingly are important for obtaining a better clinical outcome. It can help quickly select patients, who, even though they will not respond to rt-PA, may be appropriate candidates for bridging therapy.
- 28 October 2021
- Published by Taylor & Francis in Neurological Research
- Vol. 44 (4) , 353-361
Factors associated with early improvement after intravenous thrombolytic treatment in acute ischemic stroke
: The aim of this study was to determine the factors associated with early neurological improvement (ENI) in patients who experienced acute ischemic stroke and were treated with intravenous recombinant tissue plasminogen activator (IV rt-PA), and determine the relationship with the outcome at the first control. : This study included 377 patients who were treated with IV rt-PA in Izmir Dokuz Eylül University Hospital between January 2010 and October 2018. ENI was defined as a 4 or more improvement in the National Institutes of Health Stroke Scale (NIHSS) score in the first hour, the twenty-fourth hour and the seventh day when compared to the pretreatment phase. The modified Rankin Scale (mRS) 0–1 score was defined as ‘very good outcome’. : The basal NIHSS (p=0.003, p=0.003, p=0.022) was high in the first hour, twenty-fourth hour, and seventh day ENI groups. Blood urea nitrogen (BUN) level was low in the first- and twenty-fourth-hour ENI groups (p=0.007, p=0.020). Furthermore, admission glucose was low at the twenty-fourth hour and on the seventh day ENI groups (p=0.005, p=0.048). A high infarct volume was observed on magnetic resonance imaging (MRI) at the twenty-fourth hour and on the seventh day non-ENI groups (p= <0.001, p= <0.001). : Management of factors associated with ENI and determination of treatment strategies accordingly are important for obtaining a better clinical outcome. It can help quickly select patients, who, even though they will not respond to rt-PA, may be appropriate candidates for bridging therapy.